Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 4 1Phase 3 1Phase 2/3 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

beta-Thalassemia 1Neoplasms 1Hepatoblastoma 1

Interventions

Oxaliplatin 49Fluorouracil 46Capecitabine 41Cisplatin 36Gemcitabine 29Leucovorin 27Bevacizumab 21Drug Therapy 20Paclitaxel 15Folfox protocol 15Radiotherapy 14Irinotecan 14apatinib 11Neoadjuvant Therapy 11Docetaxel 11sintilimab 9S 1 (combination) 9Trastuzumab 8Sorafenib 8Nivolumab 8Surgical Procedures, Operative 7Magnetic Resonance Spectroscopy 7lenvatinib 6atezolizumab 6XELOX 6Cetuximab 6Albumin-Bound Paclitaxel 6130-nm albumin-bound paclitaxel 6tislelizumab 5pembrolizumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Sugammadex × Gastrointestinal × Clear all
NCT03728543 2018-11-02

the Efficacy and Safety of Sugammadex in Children 0-2 Years Old

Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Phase 2/3 Unknown
62 enrolled
Gastrointestinal

Neoplasms, beta-Thalassemia, Hepatoblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡